| Diagnosis |
Investigator/Sponsor |
Protocol Title & Purpose |
Eligibility |
| Thoracoabdomnal aneurysm |
W. Anthony Lee, MD, FACS
NCT01524211
|
Physician-Sponsored IDE:"Evaluation of Branch Endografts in the Treatment
of Aortic Aneurysms" |
- Adult, 18 years and older
Patient must have one of the following:
- Degenerative, atherosclerotic thoracoabdominal, suprarenal and juxtarenal
aortic aneurysms (fusiform or saccular): ≥55 mm in diameter in a male
or ≥ 50 mm in diameter in a female, or
- Thoracoabdominal aortic aneurysm with a history of growth ≥ 0.5 cm per year, or
- Penetrating ulcers: ≥ 20 mm in depth, or
- Chronic type B aortic dissections: ≥ 50 mm total aortic diameter, or
- Symptomatic pathology (aneurysm, ulcer or chronic dissection) of any size.
- Additional criteria for LP material: Iliofemoral access vessels < 8
mm or with significant atherosclerotic occlusive disease that would require
an iliac conduit as determined by the PI.
|
| Infrarenal Abdominal Aortic Aneurysms |
Bolton Medical, Inc
NCT02009644
|
IP-0008-12 A Phase II Clinical Study of the Safety and Performance of the
Treovance Stent-Graft with Navitel Delivery System for Patients with Infrarenal
Abdominal Aortic Aneurysms |
- Diagnosed with an infrarenal abdominal aortic aneurysm (AAA), with or without
iliac artery involvement
- Must have infrarenal AAA that is ≥ 4.5 cm in diameter for mails, or
≥ 4.0 cm in diameter for females, or has increased in diameter by 0.5
cm in the last 6 months
|
| Juxtarenal aortic aneurysms |
Cook Incorporated
NCT02396199
|
Evaluation of the safety and effectiveness of the Zenith p-Branch in combination
with Atrium iCAST covered stents for the treatment if paraenal or juxtarenal
aortic aneurysms. |
- Pararenal or juxtarenal AAA ≥ 5.0 cm in diameter or 2X normal aortic
diameter,or
- Pararenal or juxtarenal AAA with history of growth ≥ 0.5 cm/year, or
- Saccular aneurysm with aortic diameter < 1.5X normal aortic diameter
deemed at risk for rupture by physician
|
| Coronary Bypass |
Alexander Kulik, MD
NCT02053909
|
Ticagrelor Antiplatelet Therapy to Reduce Graft Events and Thrombosis (TARGET
Trial): Does Ticagrelor Improve Graft Patency after Coronary Bypass? |
- Female and/or male aged 18 - 90 years
- Undergoing first time CABG with at least 1 saphenous vein graft, irrespective
of concurrent valve surgery
|
|
St. Jude Medical, Inc.
NCT02832622
|
MultiPoint Pacing™ Post Market Study (MPP PMS) |
- Scheduled to receive new CRT implant or upgrade from an existing ICD/Pacemaker
implant with no prior LV lead placement
|